Questions & explanations
1. Gompertzian growth means the tumor's growth rate slows as it gets bigger. If a small tumor grows quickly and a large tumor grows slowly, when is chemotherapy most effective according to this model?
According to the Gompertzian model, chemotherapy is most effective when the tumor is small because the growth fraction (percentage of cells dividing) is high. Many chemotherapy drugs kill dividing cells, so a high growth fraction means more cells are killed. As the tumor gets larger, growth slows, so fewer cells are dividing and the drug kills a smaller fraction. This is why surgery to remove most of the tumor (debulking) can make chemotherapy more effective: the remaining small tumor grows faster and is more sensitive. The model also suggests that giving chemotherapy in cycles allows the tumor to regrow between treatments, but the regrowth is slower for larger tumors.
2. Compare the log-kill and Norton-Simon models: which one would recommend giving chemotherapy more often (dose-dense) and why?
The Norton-Simon model recommends dose-dense chemotherapy (giving treatments closer together) because it accounts for Gompertzian growth: after chemotherapy, the tumor shrinks, then regrows quickly when small. By giving the next cycle before the tumor regrows too much, you can kill more cells. The log-kill model alone does not consider growth rate changes, so it would not specifically suggest dose-dense scheduling. In practice, dose-dense regimens (e.g., every 2 weeks) have shown benefit in some cancers like breast cancer, supporting Norton-Simon. However, both models agree that multiple cycles are needed to reduce cell numbers enough for cure.
3. Why is carboplatin dosed by AUC rather than by body surface area (BSA)?
Carboplatin is mostly removed from the body by the kidneys, so its clearance depends on kidney function, not body size. Dosing by BSA (body surface area) would give very different AUCs in patients with different kidney function. For example, two patients with the same BSA but different kidney function would have different drug exposure. AUC dosing uses the Calvert formula, which includes GFR (kidney function) to give a consistent exposure. This reduces toxicity (especially low blood counts) and improves effectiveness. Other drugs like cisplatin are also dosed based on kidney function, but carboplatin is the classic example of AUC dosing.
4. Compare the barriers to clinical trial enrollment in low-income countries versus high-income countries.
In high-income countries, barriers include strict eligibility criteria, long travel distances to trial centers, and lack of awareness. But most families can access trials if they qualify. In low-income countries, barriers are more severe: no trials exist for many cancers, lack of funding, and poor infrastructure. For example, a high-income country may have 20 trials for a certain cancer, while a low-income country has none. Also, in low-income countries, families may not understand what a trial is, and there may be distrust of research. Both settings need better education and support, but low-income countries need basic resources first.
5. What can be done to increase access to clinical trials for children with cancer in low-income countries?
International collaborations can help set up trial networks that include hospitals in low-income countries. For example, the Children's Oncology Group has partnerships in some countries. Funding from governments and charities can support the necessary infrastructure, like labs and data management. Simplified trial designs that require fewer resources can be used. Training local doctors and nurses in research methods is essential. Also, drug companies can be encouraged to include low-income sites in their trials. Making trial results available quickly helps everyone. Ultimately, every child deserves a chance to benefit from research.
6. Give an example of a combination chemotherapy regimen and explain why those drugs are used together.
One common regimen is CHOP, used for non-Hodgkin lymphoma. CHOP stands for cyclophosphamide (an alkylating agent), doxorubicin (an antitumor antibiotic), vincristine (a plant alkaloid), and prednisone (a steroid). Each drug works differently: cyclophosphamide damages DNA, doxorubicin intercalates DNA, vincristine stops cell division, and prednisone reduces inflammation and kills some cancer cells. Their side effects do not overlap much—for example, cyclophosphamide can cause bladder problems, doxorubicin can affect the heart, and vincristine can cause nerve damage. This combination has been very effective for many patients.
7. How does robotic surgery help in gynecologic cancer treatment?
For gynecologic cancers like endometrial or cervical cancer, robotic surgery allows the surgeon to remove the uterus, ovaries, and lymph nodes through small cuts in the abdomen. The robot's arms can reach deep into the pelvis with precision. This results in less pain, less blood loss, and a shorter hospital stay compared to open surgery. The magnified view helps identify and avoid the ureters (tubes from kidneys to bladder) and blood vessels. For obese patients, robotic surgery is especially helpful because it avoids a large abdominal incision. Recovery is quicker, and patients can start other treatments sooner if needed.
8. What is febrile neutropenia?
Febrile neutropenia is a condition where a patient has a fever and a very low number of neutrophils, a type of white blood cell that fights infection. It is a common emergency in cancer patients after chemotherapy. Doctors start antibiotics right away without waiting for test results because infections can become severe quickly. The choice of antibiotics depends on how sick the patient looks and their risk of complications. Low-risk patients may get oral antibiotics and go home, while high-risk patients need IV antibiotics in the hospital. Treatment usually continues until the fever is gone and neutrophil counts recover.
9. Compare the impact of late effects on quality of life between a survivor treated with chemotherapy alone and one treated with chemotherapy plus stem cell transplant.
A survivor who had only chemotherapy may have fewer late effects, such as mild heart or nerve issues, but often returns to a near-normal life. In contrast, a survivor who had a stem cell transplant faces more severe late effects, including chronic graft-versus-host disease, which can affect skin, liver, and lungs. Transplant survivors also have higher risks of infections, hormone problems, and second cancers. Their quality of life is often lower due to these ongoing health issues and need for long-term medications. Both groups require regular follow-up, but transplant survivors need more intensive monitoring and support.
10. Compare the psychosocial needs of an adolescent with cancer to those of a younger child.
An adolescent with cancer often worries about missing school, losing friends, and not being independent. They may feel different from their peers. A younger child is more concerned about separation from parents and pain. Adolescents also think about their future, like career and relationships. They may rebel against treatment because they want control. For example, a teenager might skip pills to feel normal. A younger child usually follows parents' instructions. AYA programs provide psychologists and social workers to help with these issues. They also create peer support groups so teens can talk to others like them.
11. What is the main goal of VMAT optimization?
VMAT (Volumetric Modulated Arc Therapy) optimization aims to create a treatment plan where the machine rotates around the patient while continuously shaping the beam and changing the dose rate. The goal is to deliver a high dose to the tumor while keeping the dose to nearby healthy organs as low as possible. The optimizer adjusts the speed of rotation, the shape of the leaves, and the dose rate to achieve this. It uses arc sequencing to divide the full rotation into smaller arcs for better control. Dose rate modulation means the machine can deliver radiation faster or slower during different parts of the arc.
12. How can a wearable biosensor help a child with cancer during a clinical trial?
A wearable biosensor can help by continuously monitoring the child's vital signs, such as heart rate and temperature, while they are at home. If the sensor detects an abnormal change, it can alert the doctor immediately. This is important because children in cancer trials may have weakened immune systems and can get infections quickly. The sensor reduces the need for frequent clinic visits, which can be tiring for the child. It also provides more complete data than occasional check-ups. For example, a sensor might show that a child's heart rate goes up at night, which could be a side effect of the medicine.